Venus Medtech (Hangzhou) Inc.
Status: Publicly traded
Direct answer
Venus Medtech (Hangzhou) Inc. is publicly traded on HKSE under the ticker 2500.HK.
Venus Medtech (Hangzhou) Inc. specializes in the global development and commercialization of catheter-based cardiac valve solutions, operating across Mainland China and international markets. Its leading product, VenusA-Valve, is a transcatheter aortic valve replacement (TAVR) designed for treating severe aortic stenosis. Another significant offering, VenusP-Valve, functions as a transcatheter pulmonary valve system...
Can you invest in Venus Medtech (Hangzhou) Inc.?
Yes. Venus Medtech (Hangzhou) Inc. is publicly traded on HKSE under the ticker 2500.HK.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Venus Medtech (Hangzhou) Inc.
Detailed equity research is provided by MarketSnap.